NPY2R
Neuropeptide Y receptor type 2
As of the edition of 20 October 2026, NPY2R (neuropeptide Y receptor type 2, UniProt P49146) has 1 drug tested at it and 3 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P49146
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 5
- Disease areas
- Nutrition and metabolism; Cancer; Hormones; Inherited and neonatal; Mental health
- Registered trials of its drugs
- 6
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Peptide yy human (3-36) | Went quiet | Phase 2 | none listed |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Pfizer | Route A |
| Gila Therapeutics | Route A |
| Nastech Pharmaceutical | Route A |
The other 0 companies at NPY2R
In the product3 companies in all; 0 are not named here, and no score is.
See the 3 companies at NPY2R, ranked, with the facts behind eachRequest access. Nothing is shown until you do.